Eli Lilly
LLY Mega CapHealthcare · Drug Manufacturers - General
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Eli Lilly en bref
Eli Lilly (LLY) is currently trading at 959,71 € with a market capitalization of 855,8 Md €. The trailing P/E ratio stands at 39.04x, with a forward P/E of 24.72x. The 52-week range spans from 544,36 € to 1 032,14 €; the current price is 7% below the yearly high. Year-over-year revenue growth stands at +55.5%. The net profit margin stands at 34.99%.
💰 Dividende
Eli Lilly currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
29 analystes évaluent Eli Lilly (LLY) au consensus : Acheter. L'objectif de cours moyen est de 1 060,99 €, soit un potentiel de +10.55% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 741,77 € à 1 309,01 €.
Eli Lilly : la thèse d'investissement en détail
Eli Lilly (LLY) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 55.5% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 82.83%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 107.46% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.
Le scénario baissier
Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valorisation en contexte
The EV/EBITDA multiple of 28.69x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
À surveiller
- The forward P/E of 24.72x is meaningfully below the trailing 39.04x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 55.5% sur un an
- Rentable avec une marge nette de 34.99%
- Rentabilité élevée des capitaux propres (107.46% ROE)
- Marge brute élevée de 82.83% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Free cash flow positif
- –Actuellement jugée surévaluée
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Eli Lilly?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news